Under revised deal, Galapagos is entitled to over $596 million in milestones.
Galapagos and Merck & Co. expanded their existing global collaboration in metabolic diseases to cover the development of new small molecule candidates against atherosclerosis. The original deal, signed in January, covered obesity and diabetes.
The wider collaboration could see Galapagos’ research, regulatory, and sales milestone payments double to over E400 million, or roughly $596.03 million.
Under terms of the expanded agreement, Galapagos will use its target discovery platform to identify and validate novel targets in all three indications. The company will also be responsible for the discovery of new drug candidates against these targets.
Merck will have an exclusive option to license each candidate for clinical development and commercialization worldwide. Galapagos is eligible to receive royalties upon commercialization of any products covered under the agreement.